Why is this study being conducted?
This study is testing a new potential treatment for idiopathic inflammatory myopathies (IIM), which includes polymyositis (PM) and dermatomyositis (DM). The study will investigate whether the new treatment can improve the symptoms of PM and DM.
Who is eligible to participate in this study?
You may be eligible if you:
- Are 18 to 75 years of age
- Have been diagnosed with polymyositis or dermatomyositis
- Do not have other conditions affecting your muscles
Those who are interested in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?聽
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
Trial duration will be around 2 years and participants will have a screening, treatment and follow-up period.
In the first part of the study you will get either the study drug or placebo. In the second part, all participants will get the study drug.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for travel associated with each study visit.
Contact Tracey Brumby
To learn more about this clinical trial, please contact:
Tracey Brumby, Clinical Trial Coordinator.
0481 484 286 clinicaltrialunit@griffith.edu.au
This study has been approved by SVHM HREC #117/23 and GU HREC #2025/279.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials